Dokument

Summary:
Potent inhibitors of the West Nile virus NS2B-NS3 protease could be useful drugs for the treatment of WNV infections. Therefore, in the present work, new substrate analogue inhibitors against the WNV protease have been developed. In this present work, new decarboxylated arginine memtics inhibitors against the WNV NS2B-NS3 protease were developed. In comparison to the known agmatine derivatives, the P1 trans-4-Guanidinocyclohexylmethylamid containing inhibitors have higher potency and selectivity against the WNV. Moreover, the first crystal structure of the WNV protease in complex with small noncovalently-binding inhibitor was solved.

Bibliographie / References

1. Outbreak Response Working, G. The outbreak of West Nile virus infection in the New York City area in 1999. The New England journal of medicine 2001, 344, 1807-14.
2. Komar, N.; Langevin, S.; Hinten, S.; Nemeth, N.; Edwards, E.; Hettler, D.; Davis, B.; Bowen, R.; Bunning, M. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis 2003, 9, 311-22.
3. Wengler, G. Terminal sequences of the genome and replicative-from RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication. Virology 1981, 113, 544-55.
4. Chu, P. W.; Westaway, E. G. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology 1985, 140, 68-79.
5. Saupe, S. M.; Leubner, S.; Betz, M.; Klebe, G.; Steinmetzer, T. Development of new cyclic plasmin inhibitors with excellent potency and selectivity. J Med Chem 2013, 56, 820-31.
6. Immunopathology of flavivirus infections. Immunol Cell Biol 2007, 85, 33-42.
7. Lee, J. W.; Chu, J. J.; Ng, M. L. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin.
8. Girard, Y. A.; Popov, V.; Wen, J.; Han, V.; Higgs, S. Ultrastructural study of West Nile virus pathogenesis in Culex pipiens quinquefasciatus (Diptera: Culicidae).
9. Martin, J. L. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol 2009, 385, 1568-77.
10. Stoermer, M. J.; Chappell, K. J.; Liebscher, S.; Jensen, C. M.; Gan, C. H.; Gupta, P. K.; Xu, W. J.; Young, P. R.; Fairlie, D. P. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. Journal of medicinal chemistry 2008, 51, 5714-21.
11. Edition, Synthesis of Peptides and Peptidomimetics, Workbench Edition ed.; Georg Thieme Verlag Stuttgart New York, 2004; Vol. Vol. E 22a-e.
12. Walker, B.; Lynas, J. F. Strategies for the inhibition of serine proteases. Cellular and molecular life sciences : CMLS 2001, 58, 596-624.
13. Saupe, S. M.; Steinmetzer, T. A new strategy for the development of highly potent and selective plasmin inhibitors. Journal of medicinal chemistry 2012, 55, 1171-80.
14. W., 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29, 7095-101.
15. Bajusz, S.; Szell, E.; Barabas, E.; Bagdy, D. Design and synthesis of peptide inhibitors of blood coagulations. Folia haematologica 1982, 109, 16-21.
16. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem 2013, 8, 231-41.
17. Mouton, R.; Finch, D.; Davies, I.; Binks, A.; Zacharowski, K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008, 371, 475-82.
18. Campbell, G. L.; Ceianu, C. S.; Savage, H. M. Epidemic West Nile encephalitis in Romania: waiting for history to repeat itself. Annals of the New York Academy of Sciences 2001, 951, 94-101.
19. Lindenbach, B. D., H. Thiel, and C. M. Rice. Flaviviridae: The viruses and their replication. In Fields Virology, 5 ed, D. M. Knipe, and P. M. Howley, eds.
20. Heinz, F. X.; Stiasny, K. Flaviviruses and their antigenic structure. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2012, 55, 289-95.
21. Chambers, T. J.; Hahn, C. S.; Galler, R.; Rice, C. M. Flavivirus genome organization, expression, and replication. Annual review of microbiology 1990, 44, 649- 88.
22. Pierson, T. C.; Padmanabhan, R. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen.
23. H. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorganic & medicinal chemistry 2005, 13, 257-64.
24. Chu, J. J.; Ng, M. L. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. The Journal of biological chemistry 2004, 279, 54533- 41.
25. Sielaff, F.; Than, M. E.; Bevec, D.; Lindberg, I.; Steinmetzer, T. New furin inhibitors based on weakly basic amidinohydrazones. Bioorg Med Chem Lett 2011, 21, 836-40.
26. List, K. Matriptase: a culprit in cancer? Future Oncol 2009, 5, 97-104.
27. Weiss, M. S.; Brandl, M.; Suhnel, J.; Pal, D.; Hilgenfeld, R. More hydrogen bonds for the (structural) biologist. Trends in biochemical sciences 2001, 26, 521-3.
28. Eidson, M. "Neon needles" in a haystack: the advantages of passive surveillance for West Nile virus. Annals of the New York Academy of Sciences 2001, 951, 38-53.
29. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (New York, N.Y.) 1999, 286, 2333-7.
30. noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997, 40, 830-2.
31. Lim, H. A.; Ang, M. J.; Joy, J.; Poulsen, A.; Wu, W.; Ching, S. C.; Hill, J.; Chia, C. S. Novel agmatine dipeptide inhibitors against the West Nile virus NS2B/NS3 protease: a P3 and N-cap optimization study. European journal of medicinal chemistry 2013, 62, 199-205.
32. Walsmann, P. [On the purification of thrombin preparations]. Pharmazie 1968, 23, 401-2.
33. L. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerging infectious diseases 2005, 11, 1174-9.
34. Brandl, M.; Weiss, M. S.; Jabs, A.; Suhnel, J.; Hilgenfeld, R. C-H...pi-interactions in proteins. J Mol Biol 2001, 307, 357-77.
35. Frerot, E.; Coste, J.; Pantaloni, A.; Dufour, M. N.; Jouin, P. PyBop and PyBroP: Two reagents for the difficult coupling of the -dialkyl amino acid. Aib. Tetrahedron References 133
36. Lim, H. A.; Joy, J.; Hill, J.; San Brian Chia, C. Novel agmatine and agmatine-like peptidomimetic inhibitors of the West Nile virus NS2B/NS3 serine protease. European journal of medicinal chemistry 2011, 46, 3130-4.
37. Becker, G. L.; Lu, Y.; Hardes, K.; Strehlow, B.; Levesque, C.; Lindberg, I.; Sandvig, K.; Bakowsky, U.; Day, R.; Garten, W.; Steinmetzer, T. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012, 287, 21992-2003.
38. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. Biochemical and biophysical research communications 2005, 327, 589-96.
39. Stürzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikstrom, P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3- amidinophenylalanine. J Med Chem 1997, 40, 3091-9.
40. Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position. J Med Chem 1997, 40, 3687-93.
41. Brinton, M. A.; Fernandez, A. V.; Dispoto, J. H. The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology 1986, 153, 113-21.
42. Kassell, B.; Radicevic, M.; Ansfield, M. J.; Laskowski, M., Sr. The basic trypsin inhibitor of bovine pPancreas. Iv. The linear sequence of the 58 amino acids. Biochem Biophys Res Commun 1965, 18, 255-8.
43. Davies, J. S. The cyclization of peptides and depsipeptides. Journal of peptide science : an official publication of the European Peptide Society 2003, 9, 471-501. References 132
44. Brinton, M. A. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annual review of microbiology 2002, 56, 371-402.
45. Bodanszky, M.; Bodanszky, A. The practice of peptide synthesis. Springer- Verlag: Berlin ; New York, 1984; p xvii, 284 p.
46. Bodanszky, M.; Bodanszky, A. The practice of peptide synthesis. 2nd, rev. ed.; Springer-Verlag: Berlin ; New York, 1994; p xviii, 217 p.
47. Szabo, R.; Bugge, T. H. Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 2008, 40, 1297-316.
48. Suthar, M. S.; Diamond, M. S.; Gale, M., Jr. West Nile virus infection and immunity. Nature reviews. Microbiology 2013, 11, 115-28.
49. Sockett, P.; Artsob, H. West Nile virus surveillance and diagnostics: A Canadian perspective. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 2003, 14, 105-14.
50. Aleshin, A. E.; Shiryaev, S. A.; Strongin, A. Y.; Liddington, R. C. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein science : a publication of the Protein Society 2007, 16, 795- 806.
51. Sheehan, J. C.; Preston, J.; Cruickshank, P. A. A Rapid Synthesis of Oligopeptide Derivatives without Isolation of Intermediates. J Am Chem Soc 1965, 87, 2492-3.
52. Steinmetzer, T.; Schweinitz, A.; Sturzebecher, A.; Donnecke, D.; Uhland, K.; Schuster, O.; Steinmetzer, P.; Muller, F.; Friedrich, R.; Than, M. E.; Bode, W.; Sturzebecher, J. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent References 130 and selective inhibitors of matriptase. Journal of medicinal chemistry 2006, 49, 4116- 26.
53. Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. 1H-Pyrazole-1-carboxamidine hydrochloride an attractive reagent for guanylation of amines and its application to peptide synthesis. Journal of Organic Chemistry 1992, 57, 2497-502.
54. Kramer, L. D.; Styer, L. M.; Ebel, G. D. A global perspective on the epidemiology of West Nile virus. Annual review of entomology 2008, 53, 61-81.
55. Smithburn, K. C. H., T. P.; Burke, A. W.; Paul, J. H. A neurotropic virus isolated from the blood of a native of Uganda. American journal of tropical medicine 1940, 20, 471-2.
56. Schweinitz, A.; Steinmetzer, T.; Banke, I. J.; Arlt, M. J.; Sturzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Kruger, A.; Sturzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
57. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nature structural biology 2003, 10, 907-12.
58. Dixon, M. The determination of enzyme inhibitor constants. Biochem J 1953, 55, 170-1.
59. Davis, C. W.; Nguyen, H. Y.; Hanna, S. L.; Sanchez, M. D.; Doms, R. W.; Pierson, T. C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. Journal of virology 2006, 80, 1290-301.
60. S.; Strongin, A. Y. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J 2006, 393, 503-11.
61. Zhang, Y.; Corver, J.; Chipman, P. R.; Zhang, W.; Pletnev, S. V.; Sedlak, D.; Baker, T. S.; Strauss, J. H.; Kuhn, R. J.; Rossmann, M. G. Structures of immature flavivirus particles. EMBO J 2003, 22, 2604-13. References 125
62. Shiryaev, S. A.; Kozlov, I. A.; Ratnikov, B. I.; Smith, J. W.; Lebl, M.; Strongin, A. Y. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem J 2007, 401, 743-52.
63. Hubalek, Z.; Halouzka, J. West Nile fever--a reemerging mosquito-borne viral disease in Europe. Emerging infectious diseases 1999, 5, 643-50.
64. Sidique, S.; Shiryaev, S. A.; Ratnikov, B. I.; Herath, A.; Su, Y.; Strongin, A. Y.; Cosford, N. D. Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase. Bioorganic & medicinal chemistry letters 2009, 19, 5773-7.
65. Geiss, B. J.; Stahla, H.; Hannah, A. M.; Gari, A. M.; Keenan, S. M. Focus on flaviviruses: current and future drug targets. Future medicinal chemistry 2009, 1, 327- 44.
66. Garten, W.; Steinmetzer, T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010, 53, 1067-75.
67. Arroyo, J.; Miller, C.; Catalan, J.; Myers, G. A.; Ratterree, M. S.; Trent, D. W.; Monath, T. P. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. Journal of virology 2004, 78, 12497-507.
68. Harnar, J. B.; Pergam, S. A.; King, M. K.; DeMasters, B. K.; Tyler, K. L. West Nile virus neuroinvasive disease. Annals of neurology 2006, 60, 286-300.
69. Rahfeld, J.; Schierhorn, M.; Hartrodt, B.; Neubert, K.; Heins, J. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim Biophys Acta 1991, 1076, 314-6.
70. Yu, I. M.; Zhang, W.; Holdaway, H. A.; Li, L.; Kostyuchenko, V. A.; Chipman, P. R.; Kuhn, R. J.; Rossmann, M. G.; Chen, J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (New York, N.Y.) 2008, 319, 1834-7.
71. Guiheneuf, S.; Paquin, L.; Carreaux, F.; Durieu, E.; Meijer, L.; Bazureau, J. P. An efficient approach to dispacamide A and its derivatives. Org Biomol Chem 2012, 10, 978-87.

Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten